Fund shareholders of Revolution Medicines Inc
ISIN US76155X1000 · United States · LEI 549300JU3X0LBCQ65892
- Fund shareholders
- 420
- Of which ETFs
- 98 322 other funds
- Value held
- 5.1B $ 404.1M SEK · 677.8K €
- Share of capital
- 22.6 % of 214.3M shares on Jul 31, 2026
This issuer has other securities : REVOLUTION MEDICINES INC WTS 12/26 (US76155X1182)
420 funds hold this company. This table lists the 419 that declare it in a regulatory filing. 1 more fund publishes its holdings in its own report. It is not in the table.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Founders 100 ETF Founder Funds Trust | 112 | 10.9K $ | 0.49 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 106 | 15.3K $ | 0.41 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Sector Rotation Fund Meeder Funds | 106 | 10.3K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Strategic Allocation: Conservative Fund American Century Strategic Asset Allocations Inc | 101 | 14.6K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Fidelity Healthy Future Fund Fidelity Summer Street Trust | 100 | 14.4K $ | 0.10 % | 0.00 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 95 | 9.2K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Schroders Global Multi-Asset Portfolio Brighthouse Funds Trust I | 92 | 8.9K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| THRIVENT MODERATELY CONSERVATIVE ALLOCATION FUND Thrivent Mutual Funds | 86 | 12.4K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Invesco QQQ Hedged Advantage ETF Invesco Actively Managed Exchange-Traded Fund Trust | 85 | 12.3K $ | 0.10 % | 0.00 % | as of Apr 30, 2026 ↗ |
| AMG Frontier Small Cap Growth Fund AMG Funds I | 68 | 9.8K $ | 0.01 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Storebrand Global Developed Markets Storebrand Asset Management AS | 56 | 51.9K SEK | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) Russell 1000 Momentum Focus ETF SPDR SERIES TRUST | 39 | 3.8K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Columbia Research Enhanced Mid Cap ETF Columbia ETF Trust I | 39 | 3.8K $ | 0.13 % | 0.00 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Active Core U.S. Equity ETF T. Rowe Price Exchange-Traded Funds, Inc. | 35 | 3.4K $ | 0.03 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SA Schroders VCP Global Allocation Portfolio SUNAMERICA SERIES TRUST | 34 | 4.9K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| VIP Hedged Equity Portfolio Variable Insurance Products Fund VI | 33 | 3.2K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Calvert US Large-Cap Diversity, Equity and Inclusion Index ETF Morgan Stanley ETF Trust | 29 | 2.8K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| AQR Style Premia Alternative Fund AQR Funds | 1 | 97.3 $ | 0.00 % | as of Mar 31, 2026 ↗ | |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 677.8K € | 0.82 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 6.85 % | as of Apr 30, 2026 ↗ |
| Tema Oncology ETF Tema ETF Trust | 6.29 % | as of Feb 28, 2026 ↗ |
| HealthInvest Small & Mid Cap Healthcare Atle Fund Management AB | 4.13 % | as of Mar 31, 2026 ↗ |
| Marsico Midcap Growth Focus Fund MARSICO INVESTMENT FUND | 3.22 % | as of Mar 31, 2026 ↗ |
| Pinnacle Focused Opportunities ETF Tidal Trust II | 3.15 % | as of Feb 28, 2026 ↗ |
| NICHOLAS PARTNERS SMALL CAP GROWTH FUND ADVISORS' INNER CIRCLE III | 2.98 % | as of Mar 31, 2026 ↗ |
| VanEck Biotech ETF VanEck ETF Trust | 2.86 % | as of Mar 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 2.82 % | as of Apr 30, 2026 ↗ |
| Janus Henderson Transformational Growth ETF Janus Detroit Street Trust | 2.41 % | as of Apr 30, 2026 ↗ |
| Harbor Health Care ETF Harbor ETF Trust | 2.38 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 400 | +41 | 47,949,343 | -6.1 % |
| 2026Q1 | 359 | +41 | 51,041,234 | -8.6 % |
| 2025Q4 | 318 | -18 | 55,857,845 | -6.5 % |
| 2025Q3 | 336 | +10 | 59,732,762 | -7.8 % |
| 2025Q2 | 326 | +4 | 64,794,405 | +3.7 % |
| 2025Q1 | 322 | +9 | 62,505,392 | +5.6 % |
| 2024Q4 | 313 | +26 | 59,209,688 | +5.5 % |
| 2024Q3 | 287 | +20 | 56,129,869 | +4.9 % |
| 2024Q2 | 267 | +18 | 53,490,879 | +17.6 % |
| 2024Q1 | 249 | +26 | 45,498,077 | +12.7 % |
| 2023Q4 | 223 | 40,365,735 |
Institutional managers
503 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 13,604,796 | 1.3B $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 11,212,706 | 1.1B $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 9,766,496 | 949.5M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 9,555,357 | 929.3M $ | as of Mar 31, 2026 |
| FMR LLC | 8,464,314 | 823.2M $ | as of Mar 31, 2026 |
| Nextech Invest, Ltd. | 7,601,087 | 739.2M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 6,655,703 | 647.3M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 6,027,819 | 586.2M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,475,611 | 532.5M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 4,402,662 | 428.2M $ | as of Mar 31, 2026 |
| UBS Group AG | 4,386,791 | 426.6M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,338,142 | 323.9M $ | as of Mar 31, 2026 |
| Alphabet Inc. | 3,292,525 | 320.2M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3,232,213 | 314.3K $ | as of Mar 31, 2026 |
| BVF INC/IL | 2,856,782 | 277.8M $ | as of Mar 31, 2026 |
| Casdin Capital, LLC | 2,577,333 | 250.6M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 2,506,570 | 243.8M $ | as of Mar 31, 2026 |
| Holocene Advisors, LP | 2,468,644 | 240.1M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 2,375,000 | 231M $ | as of Mar 31, 2026 |
| Avoro Capital Advisors LLC | 2,344,444 | 228M $ | as of Mar 31, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2,297,000 | 223.4M $ | as of Mar 31, 2026 |
| Darwin Global Management, Ltd. | 2,211,018 | 205M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 2,185,500 | 212.5M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 2,000,000 | 194.5M $ | as of Mar 31, 2026 |
| Alyeska Investment Group, L.P. | 1,885,821 | 183.4M $ | as of Mar 31, 2026 |
Declared shareholders of Revolution Medicines Inc
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 4.90 % | 9,766,496 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Revolution Medicines Inc
12 funds declare 12 bond lines of this company. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
| Fund | Bond lines | Value | |
|---|---|---|---|
| NYLI MacKay Convertible Fund | 1 | 18.9M $ | as of Apr 30, 2026 |
| Calamos Growth & Income Fund | 1 | 12.3M $ | as of Apr 30, 2026 |
| Calamos Market Neutral Income Fund | 1 | 6M $ | as of Apr 30, 2026 |
| Calamos Convertible Fund | 1 | 5M $ | as of Apr 30, 2026 |
| Putnam Convertible Securities Fund | 1 | 4.6M $ | as of Apr 30, 2026 |
| iShares Convertible Bond ETF | 1 | 3.3M $ | as of Apr 30, 2026 |
| Calamos Global Opportunities Fund | 1 | 1.6M $ | as of Apr 30, 2026 |
| Miller Market Neutral Income Fund | 1 | 753K $ | as of Apr 30, 2026 |
| First Trust SSI Strategic Convertible Securities ETF | 1 | 568.2K $ | as of Apr 30, 2026 |
| Calamos Global Convertible Fund | 1 | 402K $ | as of Apr 30, 2026 |
| Janus Henderson Income ETF | 1 | 344.5K $ | as of Apr 30, 2026 |
| Miller Convertible Total Return ETF | 1 | 55.8K $ | as of Apr 30, 2026 |
Cite this page
Titelia. "Fund shareholders of Revolution Medicines Inc". https://titelia.com/en/stocks/revolution-medicines-inc-US76155X1000